High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.
Social Security's projected 2027 COLA raise sounds promising until you realize retirees feel higher prices months before benefits catch up. Five blue-chip dividend stocks already pay yields that outpace that adjustment, and some have raised their payouts for decades straight.
Novartis’ latest trial setback serves a cautionary tale for investors betting on big pharma’s strategy of making bite-size acquisitions to bolster their drug pipelines. In theory, smaller deals offer big pharma access to promising and potentially lucrative drugs without the risk inherent in big bets.
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.
Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
Bristol-Myers Squibb (BMY) is back in focus after presenting long term Camzyos data from the EXPLORER-LTE cohort at the 2026 European Society of Cardiology Congress in Munich. Against this backdrop, Bristol-Myers Squibb’s share price has moved to US$66.92, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%, while the 1 year total shareholder return of 47.9% points to stronger gains once dividends are included. Recent momentum has coincided with strong Q2...
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Bristol-Myers Squibb (NYSE:BMY).
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
